Skip to main navigation
Skip to search
Skip to main content
Ben-Gurion University Research Portal Home
Help & FAQ
Home
Profiles
Research output
Research units
Prizes
Press/Media
Student theses
Activities
Research Labs / Equipment
Datasets
Projects
Search by expertise, name or affiliation
Intraperitoneal chemotherapy in ovarian carcinoma
B. Piura
Research output
:
Contribution to journal
›
Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Intraperitoneal chemotherapy in ovarian carcinoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Additional Phase
14%
Advanced Stage
14%
Cisplatin
14%
Combination Chemotherapy
14%
Common Complications
14%
Consolidation Chemotherapy
42%
Cytotoxic Drugs
28%
Direct Exposure
14%
Eight-phase
14%
First-line Chemotherapy
28%
Five Stages
14%
Five-phase
14%
Further Surgery
14%
High Concentration
14%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
14%
Intraperitoneal Administration
14%
Intraperitoneal Chemotherapy
100%
Intravenous Chemotherapy
14%
Minimal Residual Disease
14%
Ovarian Cancer
14%
Ovarian Carcinoma
100%
Peritoneal Cavity
14%
Peritonitis
14%
Phase II Study
42%
Phase III Clinical Trial
14%
Primary Cytoreductive Surgery
14%
Recurring
14%
Response Rate
14%
Salvage Chemotherapy
28%
Systemic Toxicity
14%
Taxol
14%
Tumor
28%
Medicine and Dentistry
Cisplatin
14%
Clinical Trial
14%
Combination Chemotherapy
14%
Consolidation Chemotherapy
42%
Cytoreductive Surgery
14%
Cytotoxic Agent
28%
Disease
14%
First-Line Chemotherapy
28%
Hyperthermic Intraperitoneal Chemotherapy
14%
Intraperitoneal Chemotherapy
100%
Intraperitoneal Drug Administration
14%
Krukenberg Tumor
100%
Minimal Residual Disease
14%
Neoplasm
28%
Ovarian Cancer
14%
Paclitaxel
14%
Peritoneal Cavity
14%
Peritonitis
14%
Recurrent Disease
14%